Intervacc AB (publ) and the Swedish University of Agricultural Sciences, SLU, announce that they have extended the contract for the development of animal health vaccines using recombinant proteins. The successful collaboration has led to a vaccine against equine strangles approved by the European Medicines Agency, as well as promising vaccine candidates against other streptococcal and staphylococcal infections. The vaccine against equine strangles, approved by EMA and VMD, paves the way for a new generation of vaccines for bacterial infections.

Based on the same technology platform, and with a focus on the same types of bacterial infections, Intervacc is developing more safe and effective vaccines. At the forefront of our development portfolio is a prototype vaccine against Streptococcus suis infections, one of the most serious infections affecting piglets, followed by a prototype vaccine against Staphylococcus aureus, which results in mastitis, a disease of the udder in dairy cows that is difficult to treat.